• Ferrostatin-1 (Fer-1): Optimizing Ferroptosis Assays in AKI

  2026-08-03

  Ferrostatin-1 (Fer-1) is redefining ferroptosis research by offering robust, selective inhibition of iron-dependent cell death in acute kidney injury (AKI) and beyond. This guide details actionable protocols, troubleshooting strategies, and key innovations, enabling researchers to maximize reproducibility and insight in oxidative lipid damage inhibition workflows.

• Refining In Vitro Cancer Drug Response Metrics: Insights and

  2026-08-03

  Schwartz's dissertation introduces a critical framework for distinguishing proliferative arrest from cell death in in vitro cancer drug assays. This nuanced approach enables more accurate evaluation of apoptosis-targeting agents, with direct implications for the design, interpretation, and translational value of preclinical cancer research.

• Y-27632 ROCK Inhibitor: Optimizing Cytoskeletal Dynamics Res

  2026-08-02

  Y-27632 from APExBIO stands out as a selective ROCK inhibitor, enabling nuanced dissection of cytoskeletal dynamics in cancer and cell biology workflows. This guide covers protocols, troubleshooting, and experimental insights, with an emphasis on translational relevance to metastasis research.

• P2RX1 Drives Mitochondrial Apoptosis in Ph+ ALL via Ca2+/CaM

  2026-08-01

  Li et al. (2025) uncover a novel mechanism where P2RX1 overexpression in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) cells enhances mitochondrial apoptosis by disrupting calcium homeostasis, activating CaMKII, and suppressing PI3K/Akt signaling. These mechanistic insights reveal P2RX1 as a potential therapeutic target and inform improved assay strategies for programmed cell death detection.

• miR-18a/ALOXE3 Axis Drives Ferroptosis Resistance in Gliobla

  2026-07-31

  This study uncovers the mechanistic role of miR-18a in promoting glioblastoma by suppressing ALOXE3, a lipoxygenase linked to ferroptosis and cell migration. The findings provide crucial molecular insight into lipid metabolism and GPCR signaling in GBM, opening new avenues for targeted research.

• E-4031 (SKU B6077): Reliable hERG Blocker for Cardiac Resear

  2026-07-31

  This article addresses practical laboratory challenges in cardiac electrophysiology research, focusing on the use of E-4031 (SKU B6077) as a selective hERG potassium channel blocker. By presenting scenario-based Q&A blocks, we demonstrate how E-4031 delivers reliable, data-backed solutions for modeling proarrhythmic substrates and QT interval prolongation. Researchers gain actionable insights on protocol optimization, data interpretation, and product selection, grounded in recent literature and robust performance metrics.

• MCL-1’s Anti-Apoptotic Function in Breast Cancer: Evidence a

  2026-07-30

  This study demonstrates that breast cancer cells are critically dependent on the canonical anti-apoptotic function of MCL-1, as genetic deletion or pharmacological inhibition impedes tumor growth via apoptosis. The findings clarify that MCL-1’s tumor-promoting effects in breast cancer operate primarily through its role in apoptosis regulation, with implications for the development and use of selective MCL-1 inhibitors in research and therapy.

• Sulforaphane Workflows: Applied Protocols for Cancer and Inf

  2026-07-30

  Sulforaphane, a bioactive isothiocyanate, empowers research into cancer chemoprevention and oxidative stress modulation with robust, reproducible workflows. Leveraging APExBIO’s high-purity compound, researchers can model cell cycle arrest, apoptosis, and inflammasome inhibition with precision across cell and animal systems.

• Transmission Dynamics of Carbapenemase Genes in CREC, Guangd

  2026-07-29

  This study provides a detailed molecular and epidemiological analysis of carbapenemase-encoding gene (CEG) transmission in carbapenem-resistant Enterobacter cloacae (CREC) across eight hospitals in Guangdong province during the COVID-19 pandemic. The findings underscore the dominant role of plasmid-borne blaNDM-1 in multidrug resistance and offer actionable insights for infection control and antimicrobial resistance surveillance.

• Refining In Vitro Drug Response Metrics in Cancer Biology

  2026-07-29

  Schwartz's dissertation introduces a critical distinction between relative viability and fractional viability as metrics for assessing anti-cancer drug responses in vitro. By clarifying how these measures differentially capture proliferation arrest and cell death, this work advances the accuracy of apoptosis and viability assays, with broad implications for preclinical drug evaluation and cancer biology research.

• Precision Targeting of MCL-1: Strategic Insights for Transla

  2026-07-28

  This thought-leadership article bridges mechanistic insight with translational strategy, highlighting the role of the MCL-1 inhibitor A-1210477 in dissecting cancer cell survival mechanisms. Integrating recent evidence from breast cancer models and advanced workflow guidance, the piece articulates both the biological rationale and practical parameters for leveraging selective MCL-1 inhibition in cancer research, while mapping a forward-looking agenda for apoptosis-inducing therapeutics.

• Breast Cancer’s Reliance on MCL-1: Canonical Apoptosis Funct

  2026-07-28

  This study establishes that breast cancer’s dependence on MCL-1 is fundamentally linked to its classical anti-apoptotic role, rather than non-canonical functions. The findings clarify the therapeutic potential and mechanistic limits of targeting MCL-1 in breast cancer, informing both preclinical and translational research.

• Reliable Apoptosis Assays with MCL-1 Inhibitor A-1210477 (SK

  2026-07-27

  This article offers an evidence-based, scenario-driven guide for optimizing apoptosis induction and mitochondrial assays using MCL-1 inhibitor A-1210477 (SKU B6011). Drawing from recent literature and practical lab workflows, it demonstrates how this selective inhibitor from APExBIO addresses reproducibility, sensitivity, and data interpretation challenges in cancer research.

• Aerobic Activation of HIF1α by Branched Chain α-Ketoacids in

  2026-07-27

  This study reveals that branched chain α-ketoacids (BCKAs) can activate HIF1α signaling in vascular cells under normoxic conditions by inhibiting PHD2 and promoting L-2-hydroxyglutarate generation. These findings challenge the classic model of hypoxia-dependent HIF1α activation and have important implications for understanding vascular remodeling and metabolic dysregulation in diseases such as pulmonary arterial hypertension.

• Sabutoclax: Pan-Bcl-2 Inhibitor for Precision Apoptosis Assa

  2026-07-26

  Sabutoclax’s potent, multi-targeted inhibition unlocks reliable and selective apoptosis induction in cancer models, setting a new benchmark for translational research. This guide translates cutting-edge drug response metrics into actionable workflows, troubleshooting, and protocol enhancements for maximizing Sabutoclax’s value.

16130 records 1/1076 page Next 12345 下5页 Last page